REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

AOD-9604 Frag Stack

Fat Lossbeginner

81

synergy

81
Share
Peptides

2

Avg Daily mcg

600

Level

beginner

Added

May 17, 2026

Overview

The AOD-9604 Frag Stack combines AOD-9604''s direct fat-burning action with Ipamorelin''s GH pulse support, creating a two-part protocol that attacks fat during the fasted morning window and optimizes GH output during nocturnal sleep — the two periods of highest natural fat metabolism. AOD-9604 (also known as Fragment 176-191) is a modified fragment of human growth hormone''s C-terminus that retains GH''s lipolytic (fat-breaking) activity without its growth-promoting, insulin-sensitizing, or IGF-1-raising effects. This makes it unusually clean: it specifically mobilizes stored fat for energy through fat cell receptor activation without the side effects associated with full GH or GH secretagogues. It was studied in human clinical trials by Metabolic Pharmaceuticals and showed statistically significant fat reduction with minimal adverse events. Ipamorelin is dosed before sleep to amplify the natural nocturnal GH pulse — the body''s primary growth hormone secretion window. This GH pulse drives fat metabolism during sleep and supports lean tissue preservation and growth. Because Ipamorelin is highly selective (no cortisol, no appetite stimulation), it is the cleanest GHRP choice to pair with a pure fat loss compound. The timing split is intentional: AOD-9604 in the morning fasted state capitalizes on the low-insulin environment for maximum lipolysis, while Ipamorelin at night amplifies the nocturnal GH pulse. Together they target fat loss across both the AM and PM metabolic windows.

Dosing Protocol

AOD-9604 (Fragment 176-191)

daily (fasted AM)· subcutaneous

Read more about AOD-9604 (Fragment 176-191) →

300 mcg

per dose

Ipamorelin

daily (before bed)· subcutaneous

Read more about Ipamorelin →

300 mcg

per dose

Goals & Evidence

Targeted fat lossLipolysisGH optimizationBody composition
Evidence tier:Human Data

Warnings

  • AOD-9604 is not FDA-approved for weight loss. Human clinical data exists but registration was not pursued.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.